Russell Investments Group Ltd. Purchases 98,833 Shares of Cellebrite DI Ltd. (NASDAQ:CLBT)

Russell Investments Group Ltd. grew its holdings in Cellebrite DI Ltd. (NASDAQ:CLBT - Free Report) by 191.6% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 150,416 shares of the company's stock after buying an additional 98,833 shares during the quarter. Russell Investments Group Ltd. owned approximately 0.07% of Cellebrite DI worth $3,314,000 at the end of the most recent reporting period.

A number of other institutional investors have also made changes to their positions in CLBT. R Squared Ltd bought a new position in shares of Cellebrite DI in the fourth quarter worth about $100,000. Polen Capital Management LLC acquired a new position in Cellebrite DI during the 4th quarter worth $222,000. Victory Capital Management Inc. bought a new position in Cellebrite DI in the 4th quarter valued at $234,000. HighTower Advisors LLC bought a new stake in shares of Cellebrite DI during the fourth quarter worth $274,000. Finally, Pictet Asset Management Holding SA acquired a new position in shares of Cellebrite DI during the fourth quarter valued at $283,000. 45.88% of the stock is owned by institutional investors.

Analysts Set New Price Targets

CLBT has been the subject of several recent research reports. Lake Street Capital boosted their price objective on Cellebrite DI from $17.00 to $26.00 and gave the stock a "buy" rating in a report on Friday, February 14th. JPMorgan Chase & Co. increased their target price on Cellebrite DI from $24.00 to $28.00 and gave the company an "overweight" rating in a research note on Tuesday, February 11th. Finally, Needham & Company LLC reaffirmed a "buy" rating and issued a $28.00 price target on shares of Cellebrite DI in a research note on Wednesday, April 2nd. Seven research analysts have rated the stock with a buy rating, According to data from MarketBeat, Cellebrite DI presently has an average rating of "Buy" and a consensus price target of $23.43.

Cellebrite DI Price Performance

NASDAQ:CLBT traded up $0.20 on Tuesday, hitting $18.39. 824,743 shares of the company's stock were exchanged, compared to its average volume of 1,409,608. The firm has a 50-day moving average price of $18.79 and a 200-day moving average price of $20.10. Cellebrite DI Ltd. has a 52 week low of $10.25 and a 52 week high of $26.30. The company has a market cap of $4.40 billion, a P/E ratio of -13.23, a price-to-earnings-growth ratio of 4.27 and a beta of 1.44.

Cellebrite DI (NASDAQ:CLBT - Get Free Report) last announced its quarterly earnings data on Thursday, February 13th. The company reported $0.07 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.10 by ($0.03). Cellebrite DI had a positive return on equity of 58.70% and a negative net margin of 70.54%. On average, research analysts expect that Cellebrite DI Ltd. will post 0.3 earnings per share for the current fiscal year.

Cellebrite DI Profile

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.